Tirzepatide vs Retatrutide: What’s the Difference?

No. There is currently no direct randomised trial comparing tirzepatide and retatrutide in the same participants, so no one can say with confidence which produces a larger effect. Everything below compares two separate development programmes, which is a fundamentally weaker form of evidence than a randomised head-to-head comparison.

Cross-trial percentages should be read cautiously because the studies differed in population, duration, dosing, phase and design. A larger percentage in one trial is not a demonstration that one compound outperforms the other.

What can be compared directly is receptor design, development stage, and the structure of each evidence base. Those are factual properties of the compounds and their trial programmes, not contested claims about which one 'works better.'

The reason a head-to-head trial matters so much is that it is the only design that removes differences between study populations, time periods, measurement methods and dosing schedules as possible explanations for a difference in outcome. When two compounds are tested in two entirely separate trials, any gap between their reported results could reflect a genuine difference between the drugs, or it could reflect nothing more than one trial happening to enrol somewhat different people, run somewhat longer, or measure its endpoint at a different time point. Without a shared trial and a shared randomisation, there is no statistical way to rule the second explanation out.

Both compounds act on the same two incretin receptors, GIP and GLP-1; retatrutide adds a third target, the glucagon receptor, which is otherwise best known for raising blood sugar between meals but is also studied for its effect on how many calories the body burns.

Glucagon is often described as insulin's opposite number: where insulin lowers blood glucose by helping cells absorb it, glucagon raises blood glucose by signalling the liver to release stored sugar, which is one reason activating the glucagon receptor in a weight-management context might seem counterintuitive at first glance. The proposed rationale for including it in retatrutide is not about that glucose-raising action directly, but about a separate, studied effect of glucagon receptor signalling on resting energy expenditure, meaning how many calories the body burns without any change in activity.

PRECLINICAL

The glucagon receptor is the substantive mechanistic difference between the two compounds. In obese mice, retatrutide's weight effect was attributed to a combination of glucagon-driven energy expenditure, meaning the body burning more energy at rest, and GIP- and GLP-1-driven reduction in how much the animals ate. That is a different mechanistic mix from tirzepatide, not simply more of the same two pathways. [4]

Adding a receptor is a design decision with consequences in both directions. It creates an additional route to a therapeutic effect, but also an additional route to unwanted effects, which is exactly why the number of receptors targeted is not by itself a ranking of which drug is 'better.'

This distinction runs through the entire comparison below, so it is worth spelling out before looking at the trial numbers themselves. A phase 2 trial is typically smaller, often a few hundred participants, and is designed to identify a workable dose and to gather an early read on effectiveness and safety, generally over a shorter observation period than a phase 3 trial would use.

A phase 3 trial is larger, often thousands of participants, runs longer, and is designed as the definitive, pre-registered test that regulators rely on when deciding whether to approve a medicine. Larger sample sizes in phase 3 trials generally produce narrower confidence intervals, meaning a more precise estimate of the true average effect, and longer follow-up periods can reveal side effects or a loss of effect over time that a shorter phase 2 trial would not have had the chance to detect.

Tirzepatide's headline evidence, discussed in the next section, comes from completed phase 3 trials. Retatrutide's published obesity evidence, by contrast, currently stops at phase 2, with a phase 3 programme that has completed enrolment but has not yet been published in a peer-reviewed journal. That is a difference in the maturity of the evidence itself, independent of anything about how either molecule performs.

Tirzepatide's evidence base is further along: it has a completed, published phase 3 programme, while retatrutide's public evidence currently stops at phase 2.

HUMAN CLINICAL TRIAL

SURMOUNT-1 randomised 2,539 adults without diabetes over 72 weeks. Mean body-weight change was minus 15.0%, minus 19.5% and minus 20.9% at the 5, 10 and 15 mg tirzepatide doses, against minus 3.1% on placebo. [1]

HUMAN CLINICAL TRIAL

Retatrutide's published obesity trial randomised 338 adults over 48 weeks. Mean body-weight change was minus 8.7%, minus 17.1%, minus 22.8% and minus 24.2% at the 1, 4, 8 and 12 mg doses, against minus 2.1% on placebo. [2]

These two rows sit in one table for convenience only. The trials differ in phase, size, duration, dose ladder and analysis, so the difference between −20.9% and −24.2% cannot be read as a difference between the compounds themselves.

Several design differences between the two trials each independently undermine a direct comparison, and together they rule one out entirely.

• Duration differs: 72 weeks against 48 weeks, and weight trajectories had not necessarily levelled off in either trial by its endpoint.
• Size and phase differ: a 2,539-participant phase 3 trial against a 338-participant phase 2 trial, which affects how precise the estimates are and how wide their confidence intervals are.
• Populations differ in entry criteria and starting characteristics.
• Dose ladders and escalation schedules differ, and the retatrutide trial used several different starting doses within the same eventual target dose.
• Primary endpoints differ in timing: percent weight change at 72 weeks against percent weight change at 24 weeks with 48-week reporting. [1][2]

Any single one of these differences would already make a direct numerical comparison unreliable; together, they make it meaningless. The only way to know for certain which compound produces a larger effect in the same people under the same protocol is to run that trial, and no one has yet.

The point about confidence intervals deserves a further word. A smaller trial like the 338-participant retatrutide study produces wider confidence intervals around its estimate than a trial of 2,539 people would, simply because a smaller sample gives a noisier read on the true population average. A wider interval means more genuine uncertainty about the underlying number, which is one more reason a numerically larger effect in a smaller trial cannot be treated as equivalent to the same-sized effect in a larger one.

HUMAN CLINICAL TRIAL

Tirzepatide has been through exactly that kind of direct comparison once, against semaglutide 1 mg in SURPASS-2, where all three tirzepatide doses produced a greater reduction in HbA1c, with differences of 0.15 to 0.45 percentage points. [5] That is what a genuine head-to-head result looks like, and no equivalent trial exists for retatrutide.

Tirzepatide has finished the regulatory process; retatrutide has not yet started it.

Tirzepatide is approved by the FDA for type 2 diabetes as Mounjaro since May 2022, and for chronic weight management as Zepbound since November 2023.

Retatrutide is not approved anywhere. Its phase 3 TRIUMPH programme includes TRIUMPH-1 in obesity without diabetes, with an enrolment of 2,335 participants, and TRIUMPH-2 in obesity with type 2 diabetes, with an enrolment of 1,152, both listed as completed on the trial registry. [6]

'Completed' on a trial registry means that participant follow-up and data collection have finished, not that the results have been reviewed, verified and published. Peer review, in which independent scientists in the same field scrutinise a manuscript's methods and conclusions before a journal will publish it, is the additional step that turns a completed trial into evidence the wider scientific community can rely on and interrogate.

Registry status is not evidence of efficacy. As of preparation, no peer-reviewed publication of TRIUMPH-1 or TRIUMPH-2 results could be verified, and figures circulating from company communications are press-release material rather than published trial data.

2 vs 3

receptor targets

Phase 3 vs phase 2

published evidence

0

head-to-head trials

1 of 2

compounds approved

Tirzepatide is a licensed medicine backed by large, long, published, randomised trials, including one direct comparison against another approved agent. Retatrutide is an investigational compound with encouraging published phase 2 data, a completed but still-unpublished phase 3 programme, and no regulatory approval.

Those two sentences are the entire defensible comparison that the current evidence supports. Any stronger claim, such as one compound being definitively 'more effective' than the other, would require a trial that has not yet been run.

Read the compound guides in full: What is tirzepatide? and the retatrutide guide.